Skip to main content
Caplight Logo









BlueSky Immunotherapies GmbH

BlueSky Immunotherapies GmbH

Private
ViennaHealthcare & Life Scienceshttps://www.blueskyvaccines.com/

Last Round

Grant

Nov 1, 2022

Total Funding Raised

$430,000

Company Overview

BlueSky Immunotherapies GmbH is a biotechnology company that develops next-generation immunotherapies using a proprietary interferon-inducing viral vector technology platform for the treatment of cancer and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapyviral vectorbiotechnologyoncologyhuman papillomavirusHPVcancer vaccinedrug discoveryclinical trialvirotherapysolid tumor treatmentbiotech startupprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BlueSky Immunotherapies GmbH Comparables

Compare BlueSky Immunotherapies GmbH with similar companies based on industry and business-model similarity.

BlueSky Immunotherapies GmbH comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nykode Therapeutics
77%
PDS Biotechnology Corp
76%
Hookipa Pharma
75%

BlueSky Immunotherapies GmbH Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 1, 2022

BlueSky Immunotherapies GmbH Investors

Notable investors and investment history

BlueSky Immunotherapies GmbH investors
InvestorRounds
FFG Austrian Research Promotion AgencyGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    Monthly visitors increased 166% MoM.

  • Apr 2, 2026

    Monthly visitors increased 66% MoM.

BlueSky Immunotherapies GmbH Filings

Explore SEC and related filing metadata, where available.

BlueSky Immunotherapies GmbH filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about BlueSky Immunotherapies GmbH's valuation, stock price, and market status.

Is BlueSky Immunotherapies GmbH a public or private company?

BlueSky Immunotherapies GmbH is a private company.

What is the current stock price of BlueSky Immunotherapies GmbH?

BlueSky Immunotherapies GmbH is a private company with no public stock price. No recent secondary market data is available.

How much is BlueSky Immunotherapies GmbH worth (valuation)?

Valuation information for BlueSky Immunotherapies GmbH is not publicly available.

Can I buy BlueSky Immunotherapies GmbH stock?

BlueSky Immunotherapies GmbH shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was BlueSky Immunotherapies GmbH's last funding round?

BlueSky Immunotherapies GmbH's most recent funding round was Grant on November 1, 2022.

Who are the main investors in BlueSky Immunotherapies GmbH?

Key investors in BlueSky Immunotherapies GmbH include FFG Austrian Research Promotion Agency.

Will BlueSky Immunotherapies GmbH IPO soon?

No public IPO plans have been announced for BlueSky Immunotherapies GmbH.

How can I track BlueSky Immunotherapies GmbH secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BlueSky Immunotherapies GmbH's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersVienna
Employee Range2
Year Founded2013
Last FundingNov 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?